Anavex Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anavex Life Sciences şirketinin toplam hissedar öz sermayesi $129.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $141.5M ve $11.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$138.76m
Eşitlik	US$129.78m
Toplam yükümlülükler	US$11.75m
Toplam varlıklar	US$141.54m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 12X1 'nin kısa vadeli varlıkları ( $141.5M ) kısa vadeli yükümlülüklerini ( $11.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 12X1 un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 12X1 borçsuzdur.

Borcun Azaltılması: 12X1 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 12X1 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 12X1 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Anavex Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Anavex Life Sciences Corp Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Anavex Life Sciences Corp. to Report Q3, 2024 Results on Aug 06, 2024

Forecast breakeven date moved forward to 2025

Anavex Life Sciences Corp. Presents comprehensive results from the Phase IIb/III study of Blarcamesine at Alzheimer's Association Conference

Insufficient new directors

Anavex Life Sciences Corp Announces Management Appointments

Anavex Life Sciences Corp., Annual General Meeting, Jun 18, 2024

Anavex Life Sciences Corp. to Report Q2, 2024 Results on May 09, 2024

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®?3-71 in Schizophrenia

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

Anavex Life Sciences Corp. to Report Q1, 2024 Results on Feb 07, 2024

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia

Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome

Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease

New major risk - Revenue and earnings growth

Anavex Life Sciences Corp. to Report Fiscal Year 2023 Results on Nov 27, 2023

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency

Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs

Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease

Anavex Life Sciences Corp. Announces Phase 2b/3 Trial of Blarcamesine (ANAVEX 2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

Anavex Life Sciences Reports Publication of ANAVEX®?3-71 in Clinical Journal Confirming ANAVEX®? 3-71 Clinical Cardiovascular Safety

Anavex Life Sciences Corp. to Report Q3, 2023 Results on Aug 08, 2023

Anavex Life Sciences Corp. Announces Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX(R)2-73 (blarcamesine) for Rett Syndrome

Anavex Life Sciences Corp.'s ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Anavex Life Sciences Corp. Announces Completion of Anavex((R))2-73 (Blarcamesine) Excellence Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. Announces Exceeding of Enrollment Target for the ANAVEX(R)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. to Report Q1, 2023 Results on Feb 07, 2023

Anavex Life Sciences Corp. Announces the Appointment of Timo Grimmer, Md, to Its Scientific Advisory Board

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Anavex Life Sciences Corp. to Report Q4, 2022 Results on Nov 28, 2022

Insufficient new directors

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2B/3 Data of Oral Anavex®2-73 (Blarcamesine) for Early Alzheimer’s Disease At the Upcoming Clinical Trials on Alzheimer’S Disease (Ctad) Congress 2022

Forecast to breakeven in 2025

Anavex Life Sciences Corp. Reports New Publication in Medical Journal Highlighting the Relevance of Sigmar1 Activation to Compensate for Early Alzheimer's Disease

Anavex Life Sciences Corp. to Report Q3, 2022 Results on Aug 09, 2022

Anavex Life Sciences Corp. to Report Q2, 2022 Results on May 10, 2022

Insufficient new directors

Anavex Life Sciences Corp., Annual General Meeting, May 24, 2022

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome

Anavex Life Sciences Corp. to Report Q1, 2022 Results on Feb 09, 2022

Anavex Life Sciences Corp. Reports Positive Top-Line Results from the Phase 3 Randomized, Double-Blind, Placebo-Controlled AVATAR trial of ANAVEX®2-73

Anavex Life Sciences Corp. Reports Positive Results from Phase 1 Clinical Trial of ANAVEX3-71

Forecast to breakeven in 2024

No longer forecast to breakeven

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)

Anavex Life Sciences Announces Anavex 2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

Anavex Life Sciences Corp. Reports New Publication in Medical Journal Elucidating the Mechanism of Anavex®2-73 (Blarcamesine) and Anavex®3-71 (AF710B) Related to the Treatment of Alzheimer's Disease

Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (Blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease

Independent Director has left the company

Forecast breakeven pushed back to 2024

Forecast breakeven pushed back to 2024

Anavex Life Sciences Reports Anavex®2-73 (Blarcamesine) Featured as Disease-Modifying Small Molecule in Phase 3 Clinical Trials

Anavex Life Sciences Corp. to Report Q1, 2021 Results on Feb 11, 2021

New 90-day high: €5.50

Anavex Life Sciences Corp. to Report Fiscal Year 2020 Results on Dec 28, 2020

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

Anavex Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders

Anavex Life Sciences Corp. Announces Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference

New 90-day high: €5.05

Anavex Life Sciences Corp. Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia

New 90-day high: €5.00

New 90-day low - €3.18

Anavex Life Sciences Corp. to Report Q3, 2020 Results on Aug 06, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin